Details

Autor(en) / Beteiligte

• Guerrero, Camila
• Puig, Noemi
• Cedena, María-Teresa
• Calasanz, María-José
• Gutierrez, Norma C
• Fernandez, Manuela
• Oriol, Albert
• Ríos-Tamayo, Rafael
• Hernandez, Miguel-Teodoro
• Martínez-Martínez, Rafael
• Bargay, Joan
• de Arriba, Felipe
• Palomera, Luis
• Gonzalez-Rodriguez, Ana Pilar
• Gonzalez Perez, Marta-Sonia
• Orfao, Alberto
• Mateos, María-Victoria
• Martinez-Lopez, Joaquin
• Rosiñol, Laura
• Bladé, Joan
• Lahuerta, Juan-Jose
• San-Miguel, Jesus F
• Paiva, Bruno

Titel

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Ist Teil von

• Blood, 2024-02, Vol.143 (7), p.597

Ort / Verlag

United States

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify risk factors of MRD resurgence and/or progressive disease (PD) among patients achieving undetectable MRD to avoid undertreating them. Here, we studied 267 newly diagnosed transplant-eligible patients with MM enrolled in the GEM2012MENOS65 and GEM2014MAIN clinical trials who achieved MRD negativity by next-generation flow cytometry. After a median follow-up of 73 months since the first MRD negative assessment, 111 of the 267 (42%) patients showed MRD resurgence and/or PD. The only prognostic factors at diagnosis that predicted MRD resurgence and/or PD were an International Staging System (ISS) 3 and the presence of ≥0.01% circulating tumor cells (CTCs). Failure to achieve MRD negativity after induction also predicted higher risk of MRD resurgence and/or PD. Patients having 0 vs 1 vs ≥2 risk factors (ISS 3, ≥0.01% CTCs, and late MRD negativity) showed 5-year rates of MRD resurgence and/or PD of 16%, 33%, and 57%, respectively (P < .001). Thus, these easily measurable risk factors could help refine the selection of patients for whom treatment cessation after MRD negativity is being investigated in clinical trials. This trial was registered at www.clinicaltrials.gov as NCT01916252 and NCT02406144.